RO 4403726

Drug Profile

RO 4403726

Alternative Names: RO-4403726; TUB-2

Latest Information Update: 07 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antineoplastics
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 Aug 2008 Discontinued - Phase-I for Solid tumours in Belgium (IV)
  • 01 Aug 2008 Discontinued - Phase-I for Solid tumours in Netherlands (IV)
  • 01 Aug 2008 Adverse events data from a phase I trial in Solid tumours released by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top